article thumbnail

Intellia, expanding in gene editing, buys startup Rewrite for $45M

Bio Pharma Dive

Founded by University of California, Berkeley scientists, Rewrite is studying ways to expand the reach of gene editing beyond limitations of current technologies, including Intellia's.

article thumbnail

Gene editing biotechs face new uncertainty after CRISPR patent ruling

Bio Pharma Dive

A federal patent board ruled Broad Institute scientists were first to a key gene editing advance, weakening the patent position of Intellia and CRISPR Therapeutics, which hold licenses through the University of California.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Experts weigh medical advances in gene-editing with ethical dilemmas

NPR Health - Shots

The last time this summit convened in 2018, the world was shocked to hear a scientist had created the first gene-edited babies. He was condemned, but gene-editing has continued, with some success. Image credit: Anthony Wallace/AFP via Getty Images)

article thumbnail

A new startup from Feng Zhang and an ex-Illumina executive zeroes in on the epigenome

Bio Pharma Dive

Moonwalk Biosciences, the latest biotech cofounded by the gene editing scientist, joins other startups aiming to alter gene expression without changing DNA.

article thumbnail

A decade later, biotech’s CRISPR revolution is still going strong

Bio Pharma Dive

Once the specialty of a few select drugmakers, CRISPR gene editing is now an essential technology for a growing group of biotechs, many led by former students of the field's pioneering scientists.

article thumbnail

Ethical concerns temper optimism about gene-editing for human diseases

NPR Health - Shots

The Third International Summit on Genome Editing concluded Monday with ethicists warning scientists to slow down efforts to use gene-editing to enhance the health of embryos. Image credit: Mark Schiefelbein/AP)

article thumbnail

STAT+: Moderna expands CRISPR gene editing research with ElevateBio partnership

STAT News

Moderna is aiming to build a gene editing franchise powered by some of the same technologies used in its COVID-19 vaccines. The Cambridge biotech company announced Wednesday that it will partner with Life Edit Therapeutics to develop potentially permanent treatments for rare genetic diseases and other conditions.